Objective-Platelet endothelial cell adhesion molecule-1 (PECAM-1) regulates platelet response to multiple agonists. How this immunoreceptor tyrosine-based inhibitory motif-containing receptor inhibits G protein-coupled receptor-mediated thrombin-induced activation of platelets is unknown. Approach and Results-Here, we show that the activation of PECAM-1 inhibits fibrinogen binding to integrin αIIbβ3 and P-selectin surface expression in response to thrombin (0.1-3 U/mL) but not thrombin receptor-activating peptides SFLLRN (3×10 −7 -1×10 −5 mol/L) and GYPGQV (3×10 −6 -1×10 −4 mol/L). We hypothesized a role for PECAM-1 in reducing the tethering of thrombin to glycoprotein Ibα (GPIbα) on the platelet surface. We show that PECAM-1 signaling regulates the binding of fluorescein isothiocyanate-labeled thrombin to the platelet surface and reduces the levels of cell surface GPIbα by promoting its internalization, while concomitantly reducing the binding of platelets to von Willebrand factor under flow in vitro. PECAM-1-mediated internalization of GPIbα was reduced in the presence of both EGTA and cytochalasin D or latrunculin, but not either individually, and was reduced in mice in which tyrosines 747 and 759 of the cytoplasmic tail of β3 integrin were mutated to phenylalanine. Furthermore, PECAM-1 cross-linking led to a significant reduction in the phosphorylation of glycogen synthase kinase-3β Ser 9 , but interestingly an increase in glycogen synthase kinase-3α pSer 21 . PECAM-1-mediated internalization of GPIbα was reduced by inhibitors of dynamin (Dynasore) and glycogen synthase kinase-3 (CHIR99021), an effect that was enhanced in the presence of EGTA.
P latelet endothelial cell adhesion molecule-1 (PECAM-1) is a 130-kDa transmembrane glycoprotein expressed on the platelet surface at between 5000 and 8800 copies per cell. [1] [2] [3] It is composed of a 574-amino acid residue extracellular portion organized into 6 immunoglobulin-like homology domains, a 19-amino acid transmembrane domain, and a cytoplasmic domain that contains an immunoreceptor tyrosine-based inhibitory motif (ITIM; (L/V/I/S/T)XYXX(L/V)) and an immunoreceptor tyrosine-based switch motif (TxYxx(V/I)). 4, 5 The tyrosine residues (residues 663 and 686) within the ITIM and immunoreceptor tyrosine-based switch motif become tyrosine phosphorylated by Src or Csk family kinases, 6 after homophilic ligation or stimulation of platelets through protease-activated receptor (PAR)-1 and 4, glycoprotein VI (GPVI), or GPIb in a process that is largely, but not wholly, dependent on integrin αIIbβ3-dependent platelet aggregation. [7] [8] [9] [10] The inhibition by PECAM-1 of immunoreceptor signaling downstream of GPVI is well established. Once phosphorylated, these twin ITIM and immunoreceptor tyrosine-based switch motif tyrosine residues support the recruitment of Src-homology 2 domain-containing proteins, including the protein-tyrosine phosphatases SHP-2, and to a lesser extent SHP-1, 11 to which the p85 regulatory subunit of PI3K (phosphatidylinositol 3-kinase) becomes associated destabilizing its association with the LAT (linker for activation of T) cells and the scaffolding molecule Gab1 (Grb-2-associated binding protein-1). 12 By disturbing the LAT-Gab1-PI3K signaling complex, PECAM-1, therefore, disrupts the recruitment and activation of phospholipase C (PLCγ2), 12 thereby inhibiting immune-like signaling downstream of GPVI and reducing the activation of platelets by collagen, the GPVI-specific ligand cross-linked collagen-related peptide (CRP-XL) and convulxin. 10, 13, 14 More surprising is the ability of PECAM-1 to reduce platelet activation through G protein-coupled receptor (GPCR)mediated signaling pathways after stimulation by thrombin or ADP. Although hyper-reactivity to thrombin and ADP has not been detected in PECAM-1-deficient mice, 15 preactivation of PECAM-1 has been shown to reduce fibrinogen binding to platelets, secretion, and calcium mobilization in response to ADP and thrombin, 14 and in a laser injury model of thrombosis in cremaster muscle arterioles, that is dependent on thrombin generation rather than collagen exposure, 16 thrombi formed more rapidly, were more stable, and ≈35% larger in PECAM-1-deficient mice. 17 The mechanism by which PECAM-1 inhibits GPCR-mediated activation of platelets is as yet unclear.
While the inhibitory effect of PECAM-1 on individual pathways is modest, corresponding to 5% to 15% inhibition in platelet function, the physiological importance of PECAM-1 comes from its ability to inhibit multiple activation pathway. The combination of these effects account for a substantial inhibition in thrombus formation. 14, 17 We have previously reported that although PECAM-1 inhibits the activation of platelets by thrombin, it does not inhibit activation stimulated by thrombin receptor agonist peptide (TRAP). Here, we investigate this disparity and show that the activation of PECAM-1 triggers the internalization of GPIb by dual AKT/protein kinase B/glycogen synthase kinase-3 (GSK-3)/dynamin and αIIbβ3-dependent mechanisms, which result in the reduction in platelet binding of, and hence response to, thrombin and reduced platelet binding to von Willebrand factor (VWF).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Activation of PECAM-1 Inhibits the Binding of Thrombin to Human Platelets and Their Subsequent Activation
Consistent with our previous work, activating PECAM-1 by cross-linking antibodies that recognize the sixth immunoglobulin domain of PECAM-1 (AB468), resulting in PECAM-1 phosphorylation, [12] [13] [14] led to a small (5%-15%) but significant inhibition in platelet fibrinogen binding and P-selectin exposure in response to thrombin across a range of concentration (P<0.0001 and P=0.001, respectively, 2-way ANOVA; Figure 1A ). Again confirming our previous findings, PECAM-1 cross-linking did not inhibit platelet response to either PAR-1-or PAR-4-activating peptides ( Figure 1A ). The inhibition of thrombin activation of platelets without inhibiting PAR signaling suggests a role for PECAM-1 in modulating the binding of thrombin to platelets. Consistent with this cross-linking, PECAM-1 led to a significant reduction in the binding to fluorescein isothiocyanate-labeled thrombin and a concomitant reduction of platelet activation measured by the surface exposure of P-selectin ( Figure 1B This reduction of thrombin binding was specific to the activation of PECAM-1. To control for the potential steric inhibition caused by the binding and cross-linking of the PECAM-1 antibody, we repeated these experiments using a different PECAM-1 antibody (WM59) that binds PECAM-1 but prevents its activation, thereby providing a control for any steric effects. No reduction in thrombin binding was seen when platelets were incubated with antibodies against the first or second immunoglobulin domain of PECAM-1 (WM59; which prevent homophilic ligation and the activation of PECAM-1 18 ) and the cross-linking antibody ( Figure 1C) . Similarly, the binding and cross-linking of antibodies against GPIbα, GPVI, PAR-1, and PAR-4 had no effect on the binding of thrombin to the platelet surface ( Figure 1C ).
PECAM-1 Cross-Linking Reduces the Levels of GPIbα at the Cell Surface
GPIbα as part of the GPIb/V/IX complex plays an integral role in thrombin activation. It is a high-affinity receptor for thrombin 19 and acts as a cofactor for PAR cleavage. 20 Furthermore, PECAM-1 plays a role in GPIb signaling, becoming tyrosine phosphorylated on VWF binding to GPIbα, and PECAM-1-deficient mice show enhanced aggregation in response to VWF. 9 We hypothesized that the reduction in thrombin binding to platelets may be attributable to reduced surface expression of GPIbα after PECAM-1 activation. PECAM-1 cross-linking resulted in a significant reduction in the binding of antibodies against GPIbα and a reduction in antibodies against GPIbβ (Figure 2A and Figure II in the online-only Data Supplement). Although the level of GPIbα expressed on the surface of resting platelets varied among subjects, the reduction in GPIbα after PECAM-1 cross-linking occurred in all subjects. The action of PECAM-1 seemed to be specific for GPIb and did not cause a reduction in the binding of antibodies against PAR-1 and PAR-4, or GPVI (Figure 2A ).
To confirm that this reduction was attributable to PECAM-1, PECAM-1 on the surface of wild-type mouse platelets was cross-linked using antibodies that recognize the sixth immunoglobulin domain of mouse PECAM-1 (M-185) and as with human blood resulted in a significant decrease in GPIbα on the platelet surface. No such decrease was seen in PECAM-1-deficient mouse platelets ( Figure 2B ). Again to control for the effects of steric inhibitions caused by the binding and cross-linking of the PECAM-1 antibody, we repeated these experiments using a different PECAM-1 antibody (WM59) that binds PECAM-1 but prevents its activation. No reduction in GPIbα was seen when platelets were incubated with antibodies against the first or second immunoglobulin domain of PECAM-1 (WM59) and the cross-linking antibody ( Figure 2C ).
PECAM-1 Activation Inhibits Platelet Binding to VWF
Given these findings, we hypothesized that PECAM-1 crosslinking should also reduce platelet adhesion to VWF. The number of platelets in whole blood binding to VWF (100 μg/mL) under arterial flow conditions was indeed reduced after PECAM-1 cross-linking ( Figure 2D-2G ). This supports the role of PECAM-1 in regulating surface GPIbα and is in line with previous reports showing enhanced aggregation in response to VWF in PECAM-1-deficient mice. 9
PECAM-1-Mediated Reduction of Platelet Surface GPIbα Is Attributable to Internalization and Not Cleavage
We sought to determine whether the PECAM-1-mediated reduction in the surface expression of GPIbα was attributable to internalization or cleavage of the receptor. Previous reports have demonstrated the cleavage of GPIbα by ADAM17, generating a ≈95-kDa fragment and a ≈45-kDa N-terminal fragment. 21 Using a purified cobra metalloproteinase, Nk (10 μg/mL) 22 as a positive control, we identified both the ≈130-kDa intact GPIbα and the ≈95-kDa and ≈45-kDa fragments by Western blotting, using antibodies against the C-terminal and N-terminal of GPIbα respectively ( Figure 3A ). Neither of these cleaved forms of GPIbα was observed in lysates of resting, CRP-XL-stimulated, or PECAM-1-stimulated platelets, indicating that no detectable cleavage of GPIbα occurred ( Figure 3A ). Furthermore, there was no evidence of any GPIbα cleavage products in these samples. Although there is a smear in the lane of the PECAM-1-stimulated platelets, this appears at the same height when probing with both the N-terminal and C-terminal antibodies and is present in the antibody control lanes. We therefore conclude that this smear is not attributable to cleavage of GPIbα.
To further test whether GPIbα was cleaved or internalized, we measured the binding of GPIbα antibodies to nonpermeablized and permeabilized platelets. As in all previous experiments, the binding of GPIbα antibodies to nonpermeablized platelets (ie, binding solely to GPIbα expressed on the surface of platelets) decreased after PECAM-1 stimulation. There was, however, no reduction in binding of GPIbα antibodies to permeabilized platelets (ie, when the GPIb antibody could access both external and internal pools of GPIb) indicating that there Activation of platelet endothelial cell adhesion molecule-1 (PECAM-1) reduces the surface expression of glycoprotein Ibα (GPIbα) and reduces platelet binding to von Willebrand factor (vWF). A, Human platelet surface expression of GPIbα, GPIbβ, GPVI, protease-activated receptor (PAR)-1, PAR-4 in the presence (black) or absence (gray) of PECAM-1 (AB468) cross-linking was measured by flow cytometry (n=12 for anti-GPIbα and n=3 for all other experiments). B, To confirm that this was PECAM-1 specific, the expression of GPIbα on the surface of mouse platelets from wild-type (WT; n=4) or PECAM-1 knockout (KO; n=6) mice after the cross-linking of isotype control (gray) or PECAM-1 stimulatory antibodies (black) was measured. C, To check that this reduction in the surface of GPIbα was specific to the activation of PECAM-1 and not the binding of antibodies to the platelet surface, human platelet surface expression of GPIbα was measured in the presence of cross-linked isotype control (gray), PECAM-1 (WM59-inhibitory; black; n=4). The difference in median fluorescent intensity (MFI) between A and C is because they were performed on different flow cytometers, an FACSCalibur and an Accuri C6, respectively. D to G, Given the importance of GPIbα in platelet tethering to VWF, we assessed the impact of PECAM-1 cross-linking on the binding of platelets to VWF under flow. D, Representative images showing human platelets binding to VWF (100 μg/ mL) under flow conditions after the cross-linking of isotype control or PECAM-1 stimulatory antibodies, or, as a positive control, antibodies that block the binding of GPIb to VWF (Haematologic Technologies Inc). The number of human platelets binding to VWF (100 μg/mL; E), the area covered by (F), and the sum fluorescence intensity of (G) these platelets after the cross-linking of isotype control (gray) or PECAM-1 (black) stimulatory antibodies (n=3). *P<0.05, **P≤0.01, ***P<0.001.
was no loss of GPIbα from the platelets ( Figure 3B ). Taken together, these 2 pieces of evidence suggest that PECAM-1mediated reduction of platelet surface GPIbα is attributable to internalization and not cleavage.
PECAM-1 Internalization of GPIbα Is Dependent on Cytoskeletal Rearrangement and Exogenous Calcium Ions
The internalization of GPIbα is well known after platelet activation, 23 and PECAM-1 has, in other cells types, been shown to be involved in non-clathrin-mediated endocytosis. 24 To elucidate the mechanism by which PECAM-1-mediated internalization (PMI) of GPIbα occurs in platelets, the reduction in surface expression of GPIbα was measured after PECAM-1 activation in the presence of EGTA to chelate extracellular calcium ions and cytochalasin D or latrunculin and to prevent actin polymerization. Individually none of the compounds significantly inhibited PMI of GPIbα. A combination of EGTA and either cytochalasin D or latrunculin did, however, completely abrogate the effect of PECAM-1 activation on the surface expression of GPIbα ( Figure 4A ). By contrast, GPIbα internalization after stimulation of GPVI by CRP-XL was not inhibited by EGTA alone but was completely inhibited by either cytochalasin D or latrunculin ( Figure 4B ). This indicates that although GPVI-mediated internalization of GPIbα is entirely dependent on cytoskeletal rearrangement, the activation of PECAM-1 initiates 2 separate mechanisms, one dependent on cytoskeleton and the other dependent on exogenous divalent cations, both of which are capable of modulating the surface exposure of GPIbα independently.
Chelating extracellular calcium inhibits the activation of integrin αIIbβ3, the activation of which is known to be enhanced by PECAM-1. 15, 25 To establish whether integrin αIIbβ3 is involved in PMI of GPIbα, we used knock-in mice (DiYF mice) in which tyrosines 747 and 759 of the cytoplasmic tail of the β3 integrin were mutated to phenylalanine, preventing tyrosine phosphorylation and selectively impairing outside-in αIIbβ3 signaling. 26 Internalization of GPIbα after PECAM-1 cross-linking was reduced in heterozygous mice and abolished in knock-in mice ( Figure 4C ). In corroboration of our findings in humans, internalization of GPIbα after stimulation with CRP-XL was unaltered in DiYF mice ( Figure 4D ). There was no significant difference among wild-type, heterozygous, or homozygous knock-in mice in the surface expression of either αIIbβ3 or GPVI ( Figure 4E and 4F ).
PMI of GPIbα Occurs in an AKT/GSK-3/Dynamin-Dependent Manner
PECAM-1 clustering has been reported to induce dynamin-2-dependent endocytosis in endothelial cells, 24, 27 whereas in platelets, dynamin has been shown to be critical to the internalization of both P2Y 1 and P2Y 12 . 28 To investigate the role of dynamin in PMI of GPIbα, platelets were incubated with Dynasore (100 μmol/L) before antibody-mediated PECAM-1 Figure 3 . Glycoprotein Ibα (GPIbα) is internalized and not cleaved after platelet endothelial cell adhesion molecule-1 (PECAM-1) activation. A, To determine whether GPIbα is cleaved after PECAM-1 activation, human platelets that had been stimulated for 90 or 600 seconds with CRP-XL (1μg/mL), or undergone PECAM-1 activation via antibody cross-linking, or been exposed to purified cobra metalloproteinase, Nk (10 μg/mL), were probed by Western blotting (WB) using antibodies that recognize either the C-or the N-terminal domain of GPIbα. Cleavage products were clearly visible in samples treated with Nk but not CRP-XL-or PECAM-1-stimulated platelets. The smear present in the PECAM-1-stimulated samples appears at the same height when probing with both the N-terminal and C-terminal antibodies and appears when the antibodies are run alone in the absence of platelets. We therefore conclude that it is the result of protein in the stimulating antibodies rather than a result of cleavage. B, To identify the internalization of GPIbα after PECAM-1 activation, the binding of GPIbα antibodies to nonpermeablized human platelets (ie, binding to GPIbα expressed on the surface of platelets) or to permeabilized platelets (ie, binding to all GPIbα, internal and surface expressed) after PECAM-1 cross-linking was measured by flow cytometry (n=3). *P<0.05.
cross-linking. PMI of GPIbα was reduced in the presence of Dynasore and almost abolished in the presence of Dynasore and EGTA ( Figure 5A ). In part, the action of dynamin in endocytosis is regulated by the dephosphorylation (by calcineurin 29, 30 ) and rephosphorylation (by cdk5 and GSK-3 31, 32 ) of 2 serine residues in the C-terminal proline-rich domain of dynamin. Although dephosphorylation of dynamin is required for clathrin-mediated endocytosis in neurons, non-clathrin-mediated bulk endocytosis (of the type previously shown to result from PECAM-1 activation in endothelial cells 24 ) requires both dephosphorylation and rephosphorylation. 32, 33 We have previously shown that PECAM-1 cross-linking resulted in reduced phosphorylation of AKT at Ser 473 . 12 This should lead to a reduction in the phosphorylation of GSK-3, which would in turn regulate its kinase activity. After stimulation of platelets with CRP-XL, the phosphorylation of GSK-3β Ser 9 increased compared with the level in unstimulated cells; however, after PECAM-1 cross-linking, the phosphorylation of GSK-3β Ser 9 decreased (Figure 5B and 5C) . Interestingly, the same pattern was not repeated for GSK-3α. Ser 21 phosphorylation of GSK-3α did not increase significantly in response to CRP-XL but did increase significantly after PECAM-1 crosslinking ( Figure 5B and 5C) . To confirm the role of GSK-3 in PMI, we used the highly selective inhibitor of both GSK-3 isoforms, CHIR99021, which inhibited the internalization of GPIbα after the cross-linking of PECAM-1 ( Figure 5D ). Together, these data suggest that the internalization of GPIbα after PECAM-1 stimulation occurs in a non-clathrin-, AKT/ GSK-3/dynamin-dependent manner which may be similar to bulk endocytosis reported in endothelial or neuronal cells.
Discussion
Two of the enduring questions surrounding the role of PECAM-1 in regulating platelet response are how this ITIMcontaining molecule inhibits nonimmunoreceptor signaling and how a molecule with what seems to be a moderate impact on individual signaling pathways can have such a profound effect on thrombus formation in vitro and in vivo. 14, 17 By investigating the disparity between the action of PECAM-1 on platelet response to thrombin and TRAP, we have identified a PECAM-1-mediated receptor internalization pathway mediated via dual AKT/GSK-3/dynamin-and αIIbβ3-dependent mechanisms that result in the internalization of GPIbα, a reduction in thrombin binding to, and activation of, platelets, and reduced platelet binding to VWF. The physiological impact of PMI of GPIbα on the binding of platelets to vesselbound VWF is uncertain because it is unlikely that PECAM-1 is activated before platelets bind to VWF and adhere to the site of vessel damage. This novel role for PECAM-1 in platelets does, however, explain how PECAM-1 inhibits GPCRmediated activation of platelets by thrombin and why it has such a potent impact on thrombosis. By simultaneously reducing thrombin stimulation through PMI of GPIb, and GPVI signaling through its action as an ITIM-containing receptor, PECAM-1 directly regulates 2 of the major pathways by which platelets become activated and propagate thrombus formation.
PMI of GPIbα seems to occur via a distinct mechanism that is separate from the internalization of GPIbα that follows GPVI stimulation. This was seen in the internalization of GPIbα in response to CRP-XL in PECAM-1 knockout mice and the ability of cytochalasin D and latrunculin alone to inhibit CRP-XL-mediated internalization of GPIbα, but not PMI. It is likely, however, that in vivo these 2 mechanisms work in concert, particularly because PECAM-1 becomes phosphorylated after GPVI stimulation and because PECAM-1 and GPVI have opposing effects on AKT and hence GSK-3 phosphorylation. Why such opposing signaling events result in such similar outcomes is not yet known. The importance of PMI during thrombus formation may in part come from the activation of PECAM-1 by homophilic ligation, which only occurs during close platelet-platelet contact. Under these circumstances, stimulation of receptor internalization or endocytosis by PECAM-1 at the site of contact may be a mechanism for recycling receptors that are not occupied or bound into focal adhesion complexes. Trafficking these receptors away from the site of contact to areas of the platelet that are not in contact with other cells provides an attractive mechanism by which to maximize the efficiency of platelet response to multiple simultaneous stimuli and orchestrate thrombus growth.
The mechanism by which integrin β3 regulates PMI is as yet unknown. Its effect, however, seems to be critical. One explanation for this perhaps lies with filamin. Filamin binds to GPIbα in resting platelets anchoring it to the cytoskeleton, 34 helping to maintain the structure and integrity of the plasma membrane after platelet tethering to VWF under high shear. 35 On stimulation, filamin becomes detached from the cytoplasmic tail GPIbα, allowing its translocation. 36 By contrast, filamin binds to αIIbβ3 after platelet activation. One tempting hypothesis is that PECAM-1 plays a role, either directly or indirectly, in the decoupling of filamin from GPIbα and its subsequent binding to integrin β3. We have as yet been unable to confirm or refute this hypothesis, but it will be the focus of future work.
Of the 2 isoforms of GSK-3, it is the β-form that is thought to be predominant in platelets. 37 Proteomic analysis has, however, identified that the copy number per platelet for each isoform is similar, 1300 for GSK-3β and 1000 for GSK-3α. 38 Both isoforms are constitutively active in resting platelets but are inhibited by phosphorylation of Ser 21 (GSK-3α) or Ser 9 (GSK-3β) by protein kinase c or AKT on platelet stimulation. 39 It is thought that GSK-3 acts as a negative regulator of platelets; GSK-3 inhibitors increase platelet responses, GSK-3β +/− mice display increased aggregation and thrombus formation, and platelets from mice in which GSK-3α Ser 21 and GSK-3β Ser 9 have been mutated to Ala show reduced response. 37, 39 The reduction on GSK-3β pSer 9 after PECAM-1 cross-linking fits with this understanding of platelet GSK-3. PECAM-1, which has a well-established inhibitory effect on platelet signaling, reduces AKT phosphorylation and therefore reduces the phosphorylation and inhibition of GSK-3β, thereby enhancing its inhibitory effect, some of which may be mediated through dynamin and translocation of surface receptors, as we have shown to be the case with GPIb. The increase in GSK-3α phosphorylation after PECAM-1 cross-linking does not, however, fit with our current understanding. Part of the reason for this is that all previous work on GSK-3 in platelets has focused either on GSK-3β alone, as in the case of the GSK-3β +/− mice, or has assumed that both isoforms work in a similar way and have therefore inhibited both isoforms. In the case of dual inhibition, the effect of GSK-3α may be masked by GSK-3β making any interpretation of the physiological relevance of GSK-3α impossible. Although there is 85% similarity in the amino acid sequence between the isoforms and 98% homology in the kinase domain, 40 there is growing evidence that the 2 isoforms of GSK-3 have distinct roles. [41] [42] [43] Why the activation of PECAM-1 has such contrasting effects on the 2 GSK-3 isoforms and what significance GSK-3α phosphorylation has in PECAM-1 signaling are as yet unknown.
The inhibition of platelet activation by PECAM-1 is well known, but the mechanisms by which this ITIM-containing receptor inhibits platelet response to thrombin were not. Here, we have shown that the activation of PECAM-1 results in the internalization of GPIb by dual GSK-3/dynamin-and αIIbβ3-dependent mechanisms, which result in the reduction in platelet binding of, and hence response to, thrombin and reduced platelet binding to VWF. Furthermore, we have for the first time shown the differential regulation of GSK-3α/β by PECAM-1 in platelets. This novel role for PECAM-1 expands our understanding of how this promiscuous molecule regulates multiple diverse signaling pathways and why it has such a potent impact on thrombosis. It may also suggest a role for PECAM-1 in regulating conditions where the generation of thrombin and the response of platelets to thrombin are central to pathology.
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We show 2 new facets of platelet endothelial cell adhesion molecule-1 (PECAM-1) biology in platelets: (1) that PECAM-1 mediates the internalization of glycoprotein Ibα leading to a reduction in the activation of platelets by thrombin and a reduction in their binding to von Willebrand factor and (2) that PECAM-1 differentially regulates the phosphorylation of the 2 isoforms of glycogen synthase kinase-3. In so doing, this article answers several outstanding questions concerning the regulation of platelets by PECAM-1: how this immunoreceptor tyrosine-based inhibitory motif-containing molecule inhibits nonimmunoreceptor signaling and importantly, how PECAM-1 has such a profound effect on thrombus formation in vitro and in vivo.
Significance
